Tirzepatide Mechanism and Clinical Superiority

Introduction to Tirzepatide

Tirzepatide is a dual GIP/GLP-1 receptor agonist that activates two distinct receptor pathways 1, 2
The American College of Cardiology and other guideline societies may recommend tirzepatide for its dual mechanism of action, although this is not explicitly stated in the provided text, tirzepatide binds to both glucose-dependent insulinotropic polypeptide (GIP) receptors and GLP-1 receptors, though its affinity for the GLP-1 receptor is approximately five times less than that of endogenous GLP-1 3

GLP-1 receptor activation stimulates insulin secretion from pancreatic β cells, inhibits glucagon secretion, delays gastric emptying, and reduces appetite through central nervous system pathways 1, 3
GIP receptor activation augments insulin secretion and modulates glucagon secretion in a glucose-dependent manner (inhibits in hyperglycemia, augments in euglycemia/hypoglycemia) 3
Combined receptor activation produces synergistic effects on appetite regulation through hypothalamic and brainstem nuclei that mediate satiety, energy intake, and expenditure 1, 2

Tirzepatide produced greater reductions in HbA1c and body weight compared with semaglutide and dulaglutide 3
Mean weight loss of 15% at 72 weeks in non-diabetic obese patients 1, 2
Weight reductions up to 20.9% at higher doses (15 mg) 1
This degree of weight loss previously was only reported with bariatric surgery 1, 2

Glucose-dependent insulin secretion enhancement 3
Glucagon suppression at hyper/euglycemia 3
Delayed gastric emptying 1, 3
Central appetite suppression 1, 2
Cardiovascular protection through multiple pathways, as noted by medical insights, although the specific society is not mentioned 5